PPD/Applied Bioscience (Pharmaco) merger will create third largest contract research organization.
• By The Pink Sheet
PPD/APPLIED BIOSCIENCE MERGER TO CREATE THIRD LARGEST CRO with contract research "net revenue in excess of $150 mil.," the companies reported following signing of the merger agreement June 20. Total net revenue for the combined company will be $200 mil. The combined company will keep the Pharmaceutical Product Development name and headquarters in Wilmington, N.C. Applied Bioscience, a holding company headquartered in Arlington, Va., comprises the CRO Pharmaco International, the investigative site Chicago Center for Clinical Research, and an environmental sciences group, Environ, offering chemical and environmental health risk assessment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.